Reported about 18 hours ago
Novo Nordisk has successfully won a legal case against compounding pharmacies selling counterfeit versions of its GLP-1 drugs, including Ozempic. However, the ruling may not eliminate all knockoffs, as certain compounding pharmacies may exploit loopholes to continue operations. The FDA has set a deadline to cease compounded semaglutide distribution, but ongoing legal battles are expected as affected companies seek to challenge the decision.
Source: YAHOO